Buscar en
Angiología
Toda la web
Inicio Angiología Modificación de los factores de riesgo en el paciente arteriosclerótico joven:...
Información de la revista
Vol. 54. Núm. 3.
Páginas 174-181 (Enero 2002)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 54. Núm. 3.
Páginas 174-181 (Enero 2002)
DOI: 10.1016/S0003-3170(02)74742-1
Acceso a texto completo
Modificación de los factores de riesgo en el paciente arteriosclerótico joven: mecanismos implicados
Modification of risk factors in the young arteriosclerotic patient: mechanisms involved
Modificação dos factores de risco no doente arteriosclerótico jovem: mecanismos implicados
Visitas
...
J. Marrugat
Autor para correspondencia
jmarrugat@imim.es

correspondence: Unidad de Lípidos y Epidemiología Cardiovascular. Institut Municipal d'Investigació Mèdica (IMIM). Dr. Aiguader, 80. E-08003 Barcelona. Fax: +34 932 257 550.
Unidad de Lípidos y Epidemiología Cardiovascular. Institut Municipal d'Investigació Mèdica (IMIM). Barcelona, España.
Información del artículo
Summary
Introduction

Peripheral arteriopathy is an expression of arteriosclerosis which is associated with a poor prognosis. Treatment of it should therefore include measures to reduce its high cardiovascular morbimortality. The palliative measures should be accompanied by the detection and intensive treatment of the main cardiovascular risk factors. In particular smoking, diabetes mellitus and hypertension should be considered.

Objectives

The preventive measures should be full and equivalent to the measures for secondary preventive measures in persons who already have ischaemic cardiopathy.

Conclusions

Reduction of the high morbimortality due to cardiovascular disease requires an aggressive, multi-disciplinary approach and effort.

Key words:
Arteriosclerosis
Cardiovascular risk factor
Ischaemic cardiopathy
Peripheral arteriopathy
Resumen
Introducción

La arteriopatía periférica constituye una expresión de arteriosclerosis asociada a mal pronóstico y, por tanto, su tratamiento debe incluir todas las medidas que contribuyan a reducir su elevada morbimortalidad cardiovascular. Las medidas paliativas deben acompañarse de la detección y el tratamiento intensivo de los principales factores de riesgo cardiovascular; en particular, el consumo de tabaco, la diabetes mellitusy la hipertensión deben considerarse prioritarios.

Objetivos

Los objetivos preventivos deben ser máximos y equivalentes a las medidas de prevención secundaria en sujetos que ya tienen cardiopatía isquémica.

Conclusión

La disminución de la elevada morbimortalidad por enfermedad cardiovascular precisa un abordaje y un esfuerzo multidisciplinario y agresivo.

Palabras clave:
Arteriopatía periférica
Arteriosclerosis
Cardiopatía isquémica
Factores de riesgo cardiovascular
Resumo
Introdução

A arteriopatia periférica constitui uma expressão de arteriosclerose associada a prognóstico desfavorável e, portanto, o seu tratamento deve incluir todas as medidas que contribuam para reduzir a sua elevada morbimortalidade cardiovascular. As medidas paliativas devem ser acompanhadas pela detecção e o tratamento intensivo dos principais factores de risco cardiovascular. Em particular, o consumo de tabaco, a diabetes mellitus e a hipertensão, devem considerar-se prioritários.

Objectivos

Os objectivos preventivos devem ser máximos e equivalentes as medidas de prevenção secundária em individuos que já têm cardiopatia isquémica.

Conclusao

A diminuição da elevada morbilidade e mortalidade por doença cardiovascular necessita de uma abordagem e de um esforço multidisciplinar e agressivo.

Palavras clave:
Arteriopatia periférica
Arteriosclerose
Cardiopatia isquémica
Factores de risco cardiovascular
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Planas, A. Ciará, J.M. Pou, F. Vidal-Barraquer, A. Gasol, A. de Moner, et al.
Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men.
Int J Obes Relat Metab Disord, 25 (2001), pp. 1068-1070
[2.]
A.B. Newman, D.S. Siscovick, T.A. Manolio, J. Polak, L.P. Fried, N.O. Borhani, et al.
Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study.
Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation, 88 (1993), pp. 837-845
[3.]
A. Planas, A. Clará, J. Marrugat, J.M. Pou, A. Gasol, A. de Moner, et al.
Age at onset of smoking is an independent risk factor in peripheral artery disease development.
J Vasc Surg., 35 (2002), pp. 506-509
[4.]
W.R. Hiatt.
Medical treatment of peripheral arterial disease and claudication.
N Engl J Med., 344 (2001), pp. 1608-1621
[5.]
Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults.
Executive summary ofthe Third Report ofthe National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).
JAMA, 285 (2001), pp. 2486-2497
[6.]
S. Coccheri, on behalf of the CAPRIE Investigators.
Distribution of symptomatic atherothrombosis and influence of atherosclerotic disease burden on risk of secondary ischaemic events: results from CAPRIE.
Eur Heart J, 19 (1998), pp. 227
[7.]
L. Serés, V. Valle, J. Marrugat, G. Sanz, R. Masia, J. Lupon, et al.
Usefulness of hospital admission risk stratification for predicting nonfatal acute myocardial infarction or death six months later in unstable angina pectoris. RESCATE Study Group. Resources used in acute coronary syndromes and delays in treatment.
Am J Cardiol, 84 (1999), pp. 963-969
[8.]
G. Assmann, H. Schulte.
The Prospective Cardiovascular Munster (PROCAM) Study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease.
Am Heart J, 116 (1998), pp. 1713-1724
[9.]
J.R. González-Juanatey, E. Alegría, J.M. García, I. González, J. Vicente.
Impacto de la diabetes en las enfermedades cardíacas en España.
Estudio CADIOTENS 1999. Med Clin (Barc), 116 (2001), pp. 686-691
[10.]
J.M. Pou, M. Rigla.
Hipertensión arterial como factor de riesgo cardiovascular en la diabetes.
Cardiovasc Risk Factor, 5 (2001), pp. 288-294
[11.]
L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlof, D. Elmfeldt, S. Julius, et al.
Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
HOT Study Group. Lancet, 351 (1998), pp. 1755-1762
[12.]
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy.
Lancet, 355 (2000), pp. 253-259
[13.]
UK Prospective Diabetes Study Group.
Tight blood pressure control and risk of macrovascular and microsvascular complications in type 2 diabetes: UKPDS38.
Br Med J, 317 (1998), pp. 703-713
[14.]
K. Pyorala.
Ensayos cardiovasculares en la diabetes: pasado y presente.
Rev Esp Cardiol, 53 (2000), pp. 1553-1560
[15.]
A.H. Harding, D.E. Williams, S.H. Hennings, J. Mitchell, N.J. Wareham.
Is the association between dietary fat intake and insulin resistance modified by physical activity?.
Metabolism, 50 (2001), pp. 1186-1192
[16.]
N.G. Boule, E. Haddad, G.P. Kenny, G.A. Wells, R.J. Sigal.
Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials.
JAMA, 286 (2001), pp. 1218-1227
[17.]
K.Z. Walker, L.S. Piers, R.S. Putt, J.A. Jones, K. O'Dea.
Effects of regular walking on cardiovascular risk factors and body composition in normoglycemic women and men with type 2 diabetes.
Diabetes Care, 22 (1999), pp. 555-561
[18.]
J.E. Manson, G.A. Colditz, M.S. Stampher, W.C. Willett, A.S. Krolewski, B. Rosner, et al.
A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women.
Arch Intern Med., 151 (1991), pp. 1141-1147
[19.]
J. Tuomielehto, J. Linstrom, J.G. Eriksson, T.T. Valle, H. Hamalainen, P. Llanne-parikka, et al.
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
N Engl J Med., 344 (2001), pp. 1343-1350
[20.]
UK Prospective Diabetes Study (UKPDS) Group.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet, 352 (1998), pp. 837-853
[21.]
D.K.G. Anderson, L. Svardsuldd.
Long-term glycemic control relates to mortality in type II diabetes.
Diabetes Care, 18 (1995), pp. 1534-1543
[22.]
J. Bjornholt, G. Erkssen, E. Aaser, L. Sandvik, S. Nitter-Hauge, J. Jervell, et al.
Fasting blood glucose: an underestimate risk factor for cardiovascular death: results from a 22-years follow-up of healthy non-diabetic men.
Diabetes Care, 22 (1999), pp. 45-49
[23.]
G. Hertzel.
Is glucose a continuous risk factor for cardiovascular mortality.
Diabetes Care, 22 (1999), pp. 659-660
[24.]
A. Wäner, M. Rigla, A. Pérez.
Prevención de la enfermedad cardiovascular en la diabetes mellitus.
Cardiovasc Risk Factors, 10 (2001), pp. 304-312
[25.]
Antithrombotic Trialists' Collaboration.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Br Med J, 324 (2002), pp. 71-86
[26.]
CAPRIE Steering Committee.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet, 348 (1996), pp. 1329-1339
[27.]
R. Fogari, A. Zoppi, L. Corradi, P. Lazzari, A. Mugellini, P. Lusardi.
ACE inhibition but not angiotensin II antagonism reduced fibrinogen and insulin resistance in overweight hypertensive patients.
J Cardiovasc Pharmacol, 32 (1998), pp. 616-620
[28.]
L. Hanson, L.H. Lindholm, L. Niskanen, J. Lanke, K. Hedner, A. Niklason, et al.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomized trial.
Lancet, 353 (1999), pp. 611-616
[29.]
J.R. Sowers, G.L. Bakris.
Antihypertensive therapy and the risk of type 2 diabetes mellitus.
N Engl J Med., 342 (2000), pp. 969-970
[30.]
M.W. Taal, B.M. Brenner.
Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
Kidney Int, 57 (2000), pp. 1803-1817
[31.]
G. Zuanett, R. Latini, A.P. Maggioni, M. Franzosi, L. Santoro, G. Tognoni.
Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 Study.
Circulation, 96 (1997), pp. 4239-4245
[32.]
M.L. Kendall, K.P. Lynch, A. Hjalmarson, J. Kjekshus.
Beta-blockers and sudden cardiac death.
Ann Intern Med., 123 (1995), pp. 358-367
Copyright © 2002. SEACV
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.